Corix Bioscience Stock

Corix Bioscience EBIT

The EBIT of Corix Bioscience (CXBS) as of Jul 25, 2026 is -3.85 M USD. In the previous year, EBIT was -2.26 M USD — a change of 70.81% (lower).

EBIT

-3.85 MUSD

YoY

70.81%

Last updated:

In 2026, Corix Bioscience's EBIT was -3.85 M USD, a 70.81% increase from the -2.26 M USD EBIT recorded in the previous year.

The Corix Bioscience EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (undefined USD)
Date
EBIT (undefined USD)
Jan 1, 2009
0.00 base
Jan 1, 2010
0.00 base
Jan 1, 2011
0.00 base
Jan 1, 2012
0.00 base
Jan 1, 2013
0.00 base
Jan 1, 2014
0.00 base
Jan 1, 2015
0.00 base
Jan 1, 2016
0.00 base
YEAREBIT (undefined USD)
2016 -
2015 -
2014 -
2013 -
2012 -
2011 -
2010 -
2009 -
2008 -
2007 -
Access this data via the Eulerpool API

Corix Bioscience Revenue

Corix Bioscience Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2009
0.00 USD
-70,000.00 USD
-80,000.00 USD
Jan 1, 2010
0.00 USD
-150,000.00 USD
-770,000.00 USD
Jan 1, 2011
0.00 USD
-66,000.00 USD
-76,300.00 USD
Jan 1, 2012
0.00 USD
-1.69 M USD
-1.70 M USD
Jan 1, 2013
0.00 USD
-11,600.00 USD
-1.72 M USD
Jan 1, 2014
0.00 USD
-23,300.00 USD
-57,200.00 USD
Jan 1, 2015
473,100.00 USD
-2.26 M USD
-2.77 M USD
Jan 1, 2016
693,600.00 USD
-3.85 M USD
-4.43 M USD

Corix Bioscience Margins

Corix Bioscience stock margins

The Corix Bioscience margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Corix Bioscience. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Corix Bioscience.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2009
0.00 %
- %
- %
Jan 1, 2010
0.00 %
- %
- %
Jan 1, 2011
0.00 %
- %
- %
Jan 1, 2012
0.00 %
- %
- %
Jan 1, 2013
0.00 %
- %
- %
Jan 1, 2014
0.00 %
- %
- %
Jan 1, 2015
0.00 %
-476.94 %
-584.74 %
Jan 1, 2016
0.00 %
-555.67 %
-638.65 %

Corix Bioscience Stock analysis

What does Corix Bioscience do? Corix Bioscience is a company specialized in the production of cannabinoid-based products. It was founded in 2014 under the name American Housing Income Trust, a holding company focused on the American real estate market. In 2017, the company decided to restructure and change its name to Corix Bioscience. Since then, the company has become one of the leading manufacturers of CBD oils and other cannabinoid-based products. Corix Bioscience's business model is based on state-of-the-art technologies and innovation in the cannabinoid industry. The company collaborates with other firms to develop new products tailored to patient needs. The company aims to provide patients with a natural and safe alternative to conventional medical therapy. Corix Bioscience has five divisions. These include "Corix Bioscience," which focuses on the development of CBD-based products for the European market. "Corix Health" develops cannabinoid-based products specifically tailored to patient needs. "Subsidiaries" is responsible for collaborating with other companies to expand the product offering. "Licensing" offers licenses for technologies and rights to use innovative products. "Research and Development" focuses on advancing research and technologies in the cannabinoid industry. One of Corix Bioscience's most well-known products is CBD oil. It is extracted from specially bred hemp plants and is used for pain relief, anxiety, and other ailments. The company also offers CBD-based cosmetic products and food. Corix Bioscience is headquartered in Fresno, California, and is now internationally active. The company places special emphasis on the quality of its products and uses only natural and certified ingredients. Corix Bioscience advocates for fair and sustainable production and focuses on environmental protection and sustainability. The future prospects for Corix Bioscience are promising. The company operates in a forward-thinking market, focusing on innovation and sustainability. The developments in the market for cannabinoid-based products allow Corix Bioscience to expand its portfolio and offer more patients a natural alternative to conventional medical therapy. Corix Bioscience is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Corix Bioscience's EBIT

Corix Bioscience's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Corix Bioscience's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Corix Bioscience's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Corix Bioscience’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Corix Bioscience stock

EBIT of Corix Bioscience is -3.85 M USD in 2026.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Corix Bioscience

All Key Metrics — Corix Bioscience